Salk Institute Suspends Cancer Scientist Inder Verma

The prominent researcher has been put on administrative leave pending an investigation into unspecified allegations.

Written byAshley Yeager
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

FLICKR, ALFRED ESSAInder Verma, a cancer and gene therapy scientist at the Salk Institute for Biological Studies in La Jolla, CA, has been placed on administrative leave, the San Diego Union-Tribune reported Saturday (April 21). The institute has hired The Rose Group, a San Diego–based international employment law and consulting firm, to investigate allegations, not yet made public, that were reported to the institute in February.

Dan Lewis, chairman of Salk’s board of trustees, emailed the institute’s staff members late last week to inform them that a formal investigation is underway and that “effective immediately, Dr. Verma has been placed on administrative leave, pending the outcome of the investigation. He will not be performing scientific or administrative roles on behalf of the Institute during this period.”

Complaints against Verma led to his suspension as editor-in-chief of the Proceedings of the National Academy of Sciences in December.

In response to questions from Science about sexual harassment allegations, Verma responded through his lawyer in a statement: “I have never used my position at the Salk Institute to take advantage of others. I have also never engaged in any sort of intimate relationship with ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • Ashley started at The Scientist in 2018. Before joining the staff, she worked as a freelance editor and writer, a writer at the Simons Foundation, and a web producer at Science News, among other positions. She holds a bachelor’s degree in journalism from the University of Tennessee, Knoxville, and a master’s degree in science writing from MIT. Ashley edits the Scientist to Watch and Profile sections of the magazine and writes news, features, and other stories for both online and print.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies